COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

08/03/2019 - 14:00

Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019 Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for Lymphodepletion in Patients with Relapsed/Refractory [...]

AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena® (hydroxyprogesterone caproate injection)

08/03/2019 - 14:00

WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a randomized, double-blinded [...]

Blissco Ships Initial Order to BC Liquor Distribution Branch

08/03/2019 - 14:00

Not for distribution in the U.S. or to U.S. Newswires VANCOUVER, British Columbia, March 08, 2019 (GLOBE NEWSWIRE) -- Blissco Cannabis Corp. ( CSE: BLIS ) ( OTCQB: HSTRF ) ( FRA: GQ4B ), (“Blissco”) or the (“Company”) [...]

BioSig Technologies to Present at the LD Micro Virtual Conference

08/03/2019 - 13:52

Santa Monica, CA, March 08, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed [...]

Strongbridge Biopharma plc Announces New Employment Inducement Awards

08/03/2019 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]

TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials

08/03/2019 - 13:30

UNITY-CLL DSMB conducted a pre-planned futility analysis of progression-free survival, and determined that the study was not futile and should continue as planned No safety concerns identified by the independent DSMBs [...]

New Trogarzo® Data Presented at Conference on Retroviruses and Opportunistic Infections demonstrates Sustained Viral Suppression at Week 96

08/03/2019 - 13:29

MONTREAL, March 08, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new data, presented today at the 26 th annual Conference on Retroviruses and Opportunistic [...]

De nouvelles données sur Trogarzo(MD), présentées lors de la Conference on Retroviruses and Opportunistic Infections, démontrent une suppression virale continue à la 96e semaine de traitement

08/03/2019 - 13:29

MONTRÉAL, 08 mars 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que de nouvelles données de 96 semaines, présentées lors de la 26 ième édition de la Conference on [...]

Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update

08/03/2019 - 13:00

Eloxx announces the hiring of Dr. Susan Schneider as SVP Ophthalmology to lead the development of its rare inherited retinal disease programs Abstract accepted for presentation at European Cystic Fibrosis Society (ECFS [...]

Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019

08/03/2019 - 13:00

BUFFALO, N.Y., March 08, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

PLx Pharma Inc. Reports Fourth Quarter 2018 Results

08/03/2019 - 12:50

– Company Completes Successful $15 Million Financing – HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused [...]

ChromaDex Brings TRU NIAGEN® to SXSW® 2019

08/03/2019 - 12:30

TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals LOS ANGELES, March 08, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its [...]

Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

08/03/2019 - 12:00

Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; [...]

Achillion to Present at the Barclays Global Healthcare Conference

08/03/2019 - 12:00

BLUE BELL, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by [...]

Trading in GN Store Nord shares by board members, executives and associated persons

08/03/2019 - 10:48

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]

Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

08/03/2019 - 10:10

Orphazyme A/S Company announcement No. 09/2019 Company Registration No. 32266355 Copenhagen, Denmark, March 8, 2019 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), [...]

Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer

08/03/2019 - 09:00

Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development [...]

EssilorLuxottica: 2018 pro forma results - Solid growth, sound profitability and cash flow - A robust foundation for EssilorLuxottica

08/03/2019 - 08:23

2018 pro forma 1 results Solid growth, sound profitability and cash flow A robust foundation for EssilorLuxottica PDF Version of the news release Pro forma 1 revenue: +3.2% at constant exchange rates 3 Pro forma 1 [...]

EssilorLuxottica: Résultats pro forma 2018 - Croissance, rentabilité et trésorerie solides - Un socle robuste pour EssilorLuxottica

08/03/2019 - 08:23

Résultats pro forma 1 2018 Croissance, rentabilité et trésorerie solides Un socle robuste pour EssilorLuxottica Version pdf du communiqué Chiffre d'affaires pro forma 1 : + 3,2 % à taux de change constants 3 Résultat [...]